



Suite 518, Level 5  
165-167 Phillip Street  
Sydney NSW Australia 2000

PO Box H100  
Australia Square NSW Australia 1215

T +61 2 8098 0819

F +61 2 8080 8315

[www.mmjphytotech.com.au](http://www.mmjphytotech.com.au)

[info@mmjphytotech.com.au](mailto:info@mmjphytotech.com.au)

ABN 91 601 236 417

## ASX RELEASE

28 September 2018

### Postponement of General Meeting

**MMJ PhytoTech Limited (ASX: MMJ) (MMJ)** advises that, in accordance with MMJ's constitution, the General Meeting of Shareholders scheduled for 2pm (AEST) today (the **Meeting**) has been postponed until 2pm AEST on Friday, 5 October 2018.

As announced on 25 June 2018, MMJ entered into a binding share sale agreement pursuant to which it has conditionally agreed to sell its wholly-owned subsidiary PhytoTech Therapeutics Ltd (**PTL**) to Harvest One Cannabis Inc. (TSXV: HVT) (**HVT**) for total consideration of CAD\$8 million (**Disposal**).

The Disposal is conditional upon (amongst other things) MMJ and HVT seeking all necessary shareholder and regulatory approvals required to undertake the Disposal. HVT is listed on the Canadian TSX Venture Exchange (**TSXV**) and requires approval from the TSXV to allow the Disposal to complete.

HVT has advised MMJ that the TSXV are in the final stages of considering providing its unconditional approval of the Disposal and accordingly MMJ believes it is appropriate to postpone the MMJ shareholder meeting until the approval is granted. MMJ reasonably anticipates that the approval will be granted next week. Accordingly, the details of the postponed Meeting are as follows, unless otherwise determined by the Board:

<b>Date</b>	<b>Friday, 5 October 2018</b>
<b>Time</b>	<b>2pm (AEST)</b>
<b>Venue</b>	The Westin Sydney  1 Martin Place Sydney NSW 2000 Australia

Proxy forms previously sent to shareholders may continue to be used for the postponed Meeting and proxies already cast in relation to the Meeting remain valid unless withdrawn prior to the postponed Meeting date. As a result of the postponement of the Meeting, proxy forms (if not already submitted), must be received by 2pm AEST on 3 October 2018.

-----

#### Investor and Media Enquiries

Jason Conroy  
Chief Executive Officer

#### **Note regarding suspension in the trading of MMJ shares from the day of the Meeting**

MMJ will be suspended from trading on the ASX for the period between the Meeting and the settlement of the Disposal, when it is expected that the ASX will re-admit MMJ's securities to trading on the ASX (subject to MMJ's re-compliance with Chapters 1 and 2 of the ASX Listing Rules).

**About MMJ**

MMJ is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjphytotech.com.au/investors/>

**Important Notice**

*This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.*